Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
1．Number of Data-submitting Facilities* (1,947 facilities)
11.3% (6 facilities)≧ 900 beds
N=53

88.7% (47 facilities)

18.7% (67 facilities)
500 - 899 beds
N=358

81.3% (291 facilities)

200 - 499 beds

45.2% (996 facilities)

N=2,203

JANIS
Members†
JANIS NonMembers‡

54.8% (1,207 facilities)

10.6% (613 facilities)< 200 beds
N=5,798

89.4% (5,185 facilities)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

*Data-submitting Facilities indicate facilities included in Annual Open Report 2018.
†Number of JANIS Members = Number of facilities included in Annual Open Report 2018.
‡Number of JANIS Non-members = (Number of facilities nationwide in 2017¶）－（Number of facilities included in Annual Open Report
2018）

Number of beds

Number of facilities nationwide
in 2017¶

Number of Facilities Included in Annual Open Report 2018
(percentage of facilities nationwide)≧ 900 beds

53

47

( 88.7% )500 - 899 bed

358

291

( 81.3% )200 - 499 bed

2,203

996

( 45.2% )< 200 beds

5,798

613

( 10.6% )

-

0

8,412

1,947

Unknown
Total

(

-

( 23.1% )¶Data of medical facilities is referred to Vital Statistics 2017.

1
This Open Report does not cover every data from facilities nationwide.

)

Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division

2．Number of Data-submitting Facilities,
Specimens and Isolates Counted by Specimen Source
Specimen Sources

Number of facilities
included in Annual Open
Report 2018

Number of Specimens

Number of culture-positive
specimens(Number of isolates)

Respiratory

1,946

2,221,362

1,379,427(2,834,948)

Urine

1,943

1,099,593

604,629(912,065)

Feces

1,928

575,737

257,434(485,651)

Blood

1,937

2,832,767

363,460(406,112)

Cerebrospinal fluid

1,447

86,877

4,021(4,373)

Others

1,944

1,406,134

648,517(1,144,000)

Total

1,947

8,222,470

3,257,488(5,787,149)

Inpatient specimens are counted.
All isolated bacteria except Isolated Bacterial Code 9999 (comments only) are counted.
Each specimen includes corresponding specimen source codes as below.
Respiratory : 101 (Sputum), 102 (Endotracheal aspirate), 103 (Bronchoalveolar lavage), 104 (Throat),
105 (Nasal), 106 (Oral), 107 (Lung biopsy), 109 (Other Respiratory) and 404 (Pleural
effusion)
Urinary : 201 (Urine), 202 (Urine collected by catheter), 203 (Urine obtained from indwelling catheter)and 206 (Catheterized urine)
Feces : 301 (Feces)
Blood : 401 (Venous blood) and 402 (Arterial blood)
Cerebrospinal fluid : 403 (Cerebrospinal fluid)
Others : Specimen codes not indicated above
Specimen Source Code : https://janis.mhlw.go.jp/section/kensa.html

2This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division

3．Isolated Bacteria from Blood Specimens
Blood Isolates (N=406,112)
0

20,00040,00060,00080,00071,308 (17.6%)

Escherichia coli

54,874 (13.5%)

Staphylococcus aureus

43,613 (10.7%)

Staphylococcus epidermidis

37,866 (9.3%)

Coagulase-negative staphylococci (CNS)*

27,582 (6.8%)

Klebsiella pneumoniae
Enterococcus faecalis

12,745 (3.1%)

Pseudomonas aeruginosa

11,358 (2.8%)

Enterococcus faecium

9,703 (2.4%)

Enterobacter cloacae

8,429 (2.1%)

Candida albicans

6,821 (1.7%)

Klebsiella oxytoca

6,575 (1.6%)

Corynebacterium sp.

6,036 (1.5%)

Bacillus cereus

5,184 (1.3%)

Streptococcus sp.

4,910 (1.2%)

Bacillus sp.

4,641 (1.1%)

Others 94,467 (23.3%)*Coagulase-negative staphylococci correspond to Isolated Bacterial Codes 1311, 1313-1325 (except Code 1312,Staphylococcus
epidermidis)

All inpatient speciments are counted (contaminants are not excluded).
Others include Isolated Bacterial Code 9998 (other species) and bacteria ranked 16th and lower.
All isolated bacteria except Bacterial Code 9999 (comments only) are counted.
Specimen reported as Specimen Source Code 401 (venous blood) and Code 402 (arterial blood) arecounted.
Percentage of Corresponding Blood Isolates =(Number of Corresponding Blood Isolates ) / (Total Number of Blood Isolates ) x 100
Isolated Bacterial Code : https://janis.mhlw.go.jp/section/kensa.html
Specimen Source Code : https://janis.mhlw.go.jp/section/kensa.html

3This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division

3．Isolated Bacteria from Cerebrospinal Fluid Specimens
Cerebrospinal Fluid Isolates (N=4,373)
0

200

400

600

800

830 (19.0%)

Staphylococcus epidermidis

587 (13.4%)

Coagulase-negative staphylococci (CNS)*

506 (11.6%)

Staphylococcus aureus
Corynebacterium sp.

1,000

210 (4.8%)

Propionibacterium acnes

184 (4.2%)

Cryptococcus neoformans

177 (4.0%)

Escherichia coli

146 (3.3%)

Enterococcus faecalis

134 (3.1%)

Streptococcus pneumoniae

115 (2.6%)

Pseudomonas aeruginosa

109 (2.5%)

Streptococcus agalactiae

99 (2.3%)

Klebsiella pneumoniae

91 (2.1%)

Klebsiella(Enterobacter) aerogenes

73 (1.7%)

Enterobacter cloacae

72 (1.6%)

Staphylococcus sp.

62 (1.4%)

Others 978 (22.4%)*Coagulase-negative staphylococci correspond to Isolated Bacterial Codes 1311, 1313-1325 (except Code 1312,Staphylococcus
epidermidis)

All inpatient speciments are counted (contaminants are not excluded).
Others include Isolated Bacterial Code 9998 (other species) and bacteria ranked 16th and lower.
All isolated bacteria except Bacterial Code 9999 (comments only) are counted.
Specimen reported as Specimen Source Code 403 (Cerebrospinal Fluid Samples) are counted.
Percentage of Corresponding Cerebrospinal Fluid Isolates =(Number of Corresponding Cerebrospinal Fluid Isolates ) / (Total Number of Cerebrospinal Fluid
Isolates ) x 100
Isolated Bacterial Code : https://janis.mhlw.go.jp/section/kensa.html
Specimen Source Code : https://janis.mhlw.go.jp/section/kensa.html

4This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division

3．Isolated Bacteria from Respiratory Specimens
Respiratory Isolates (N=2,834,948)0

100,000 200,000 300,000 400,000 500,000

387,080 (13.7%)

Staphylococcus aureus

318,001 (11.2%)

α-Streptococcus
Neisseria sp.

168,093 (5.9%)

Candida albicans

167,971 (5.9%)

Pseudomonas aeruginosa

165,896 (5.9%)

Corynebacterium sp.

161,423 (5.7%)
143,939 (5.1%)

Coagulase-negative staphylococci (CNS)*

106,341 (3.8%)

Klebsiella pneumoniae
Escherichia coli

75,202 (2.7%)

Candida sp.

64,684 (2.3%)

Haemophilus influenzae

61,586 (2.2%)

γ-Streptococcus

55,930 (2.0%)

Candida glabrata55,554 (2.0%)

Stenotrophomonas maltophilia

48,358 (1.7%)

Moraxella (Branhamella) catarrhalis

46,497 (1.6%)

Others 808,393 (28.5%)*Coagulase-negative staphylococci correspond to Isolated Bacterial Codes 1311, 1313-1325 (except Code 1312,Staphylococcus
epidermidis)

All inpatient speciments are counted (including commensals).
Others include Isolated Bacterial Code 9998 (other species) and bacteria ranked 16th and lower.
All isolated bacteria except Bacterial Code 9999 (comments only) are counted.
Specimen reported as Specimen Source Code 101 (Sputum) and Code 102 (Endotracheal aspirate)
and Code 103 (Bronchoalveolar lavage) and Code 104 (Throat) and Code 105 (Nasal) and Code 106(Oral) and Code 107 (Lung biopsy) and Code 109 (Other （Respiratory)) and Code 404 (Pleural
effusion) are counted.
Percentage of Corresponding Respiratory Isolates =(Number of Corresponding Respiratory Isolates ) / (Total Number of Respiratory Isolates ) x 100
Isolated Bacterial Code : https://janis.mhlw.go.jp/section/kensa.html
Specimen Source Code : https://janis.mhlw.go.jp/section/kensa.html
5This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division

3．Isolated Bacteria from Urine Specimens
Urine Isolates (N=912,065)
0

50,000100,000 150,000 200,000 250,000

232,838 (25.5%)

Escherichia coli

85,612 (9.4%)

Enterococcus faecalis
Pseudomonas aeruginosa

60,626 (6.6%)

Klebsiella pneumoniae

55,989 (6.1%)

Corynebacterium sp.

41,066 (4.5%)

Coagulase-negative staphylococci (CNS)*

37,936 (4.2%)

Candida albicans

32,779 (3.6%)

Staphylococcus aureus

31,501 (3.5%)

Enterococcus faecium

26,578 (2.9%)

Proteus mirabilis

21,648 (2.4%)

Enterococcus sp.

20,064 (2.2%)

α-Streptococcus

17,197 (1.9%)

Streptococcus agalactiae

16,534 (1.8%)

Candida glabrata15,269 (1.7%)

Klebsiella oxytoca

14,430 (1.6%)

Others 201,998 (22.1%)*Coagulase-negative staphylococci correspond to Isolated Bacterial Codes 1311, 1313-1325 (except Code 1312,Staphylococcus
epidermidis)

All inpatient speciments are counted (contaminants are not excluded).
Others include Isolated Bacterial Code 9998 (other species) and bacteria ranked 16th and lower.
All isolated bacteria except Bacterial Code 9999 (comments only) are counted.
Specimen reported as Specimen Source Code 201 (Urine) and Code 202 (Urine collected by catheter)
and Code 203 (Urine obtained from indwelling catheter) and Code 206 (Catheterized urine) arecounted.
Percentage of Corresponding Urine Isolates =(Number of Corresponding Urine Isolates ) / (Total Number of Urine Isolates ) x 100
Isolated Bacterial Code : https://janis.mhlw.go.jp/section/kensa.html
Specimen Source Code : https://janis.mhlw.go.jp/section/kensa.html
6This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division

4．Number of Patients* and Isolation Rate of Major Bacteria
Number of Patients

Distribution of(Total Isolation Rate‡)

2014

2015

2016

2017

2018

1,747,538 cases

2,551,541 cases

2,745,096 cases

2,818,296 cases

2,891,652 cases(451.6)(447.8)※246,030 cases

349,743 cases

372,787 cases

383,006 cases

391,316 cases(14.08%)(13.71%)(13.58%)(13.59%)(13.53%)74,651 cases

99,594 cases

102,216 cases

101,567 cases

101,276 cases(4.27%)(3.90%)(3.72%)(3.60%)(3.50%)

S. pneumoniae

32,256 cases

43,390 cases

42,708 cases

40,817 cases

39,194 cases(1.85%)(1.70%)(1.56%)(1.45%)(1.36%)

E. faecalis

93,822 cases

130,647 cases

139,873 cases

142,142 cases

145,286 cases(5.37%)(5.12%)(5.10%)(5.04%)(5.02%)

E. faecium

32,300 cases

46,969 cases

51,558 cases

54,868 cases

56,809 cases(1.85%)(1.84%)(1.88%)(1.95%)(1.96%)

E. coli

214,281 cases

322,142 cases

358,746 cases

380,098 cases

399,752 cases(12.26%)(12.63%)(13.07%)(13.49%)(13.82%)

K. pneumoniae

103,737 cases

150,147 cases

169,073 cases

174,820 cases

182,983 cases(5.94%)(5.88%)(6.16%)(6.20%)(6.33%)

Enterobacter spp.

67,752 cases

96,837 cases

105,645 cases

108,433 cases

114,831 cases(3.88%)(3.80%)(3.85%)(3.85%)(3.97%)

-

-

-

-

746,255 cases

-

-

-

-

(25.81%)

113,011 cases

163,631 cases

180,065 cases

184,472 cases

187,958 cases(6.47%)(6.41%)(6.56%)(6.55%)(6.50%)

23,161 cases

30,277 cases

32,270 cases

30,154 cases

30,903 cases(1.33%)(1.19%)(1.18%)(1.07%)(1.07%)

Number of Specimensubmitting Patients
S. aureus
S. epidermidis

Enterobacteriaceae
P. aeruginosa
Acinetobacter spp.

Isolation Rates (%)¶
among Data-submitting Facilities†

Inpatient specimens are counted.
*The number of duplicates within 30 days is not recounted for Patients with Major Bacteria andSpecimen-submitting Patients (See Appendix).
‡Total Isolation Rate = （Total Number of Patients with Major Bacteria for Data-submitting Facilities )/ (Total Number of Specimen-submitting Patients for Data-submitting Facilities) x 100¶Isolation Rate = (Number of Patients with Major Bacteria for Each Facility) / (Number of Specimensubmitting Patients for Each Facility) x 100†Data-submitting Facilities indicate facilities included in Annual Open Report 2018

7

This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division

5．Number of Patients* and Isolation Rate of Speciﬁc AMR Bacteria
Number of Patients

Distribution of(Total Isolation Rate‡)

Number of Specimen-submitting
Patients

Methicillin-resistant Staphylococcus
aureus(MRSA)
Vancomycin-resistant Staphylococcus
aureus(VRSA)
Vancomycin-resistantEnterococci(VRE)
Penicillin-resistant Streptococcus
pneumoniae(PRSP)
Multidrug-resistant Pseudomonas
aeruginosa(MDRP)
Multidrug-resistant Acinetobacterspp.(MDRA)
Carbapenem-resistantEnterobacteriaceae(CRE)
Carbapenem-resistant Pseudomonas
aeruginosa
3rd Generation Cephalosporinresistant Klebsiella pneumoniae
3rd Generation Cephalosporinresistant Escherichia coli
Fluoroquinolone-resistant Escherichia
coli

2014

2015

2016

2017

2018

1,747,538 cases

2,551,541 cases

2,745,096 cases

2,818,296 cases

2,891,652 cases(451.6)(447.8)※120,702 cases

169,528 cases

177,768 cases

182,619 cases

185,709 cases(6.91%)(6.64%)(6.48%)(6.48%)(6.42%)

0 cases

0 cases

0 cases

0 cases

0 cases(0.00%)(0.00%)(0.00%)(0.00%)(0.00%)

334 cases

465 cases

642 cases

684 cases

697 cases(0.02%)(0.02%)(0.02%)(0.02%)(0.02%)

11,984 cases

16,236 cases

15,608 cases

14,724 cases

14,139 cases(0.69%)(0.64%)(0.57%)(0.52%)(0.49%)

1,489 cases

1,804 cases

1,655 cases

1,410 cases

1,082 cases(0.09%)(0.07%)(0.06%)(0.05%)(0.04%)

116 cases

143 cases

130 cases

80 cases

99 cases(0.01%)(0.01%)(0.00%)(0.00%)(0.00%)

8,582 cases

9,254 cases

7,827 cases

7,572 cases

9,304 cases(0.49%)(0.36%)(0.29%)(0.27%)(0.32%)

15,369 cases

21,487 cases

22,506 cases

21,668 cases

21,202 cases(0.88%)(0.84%)(0.82%)(0.77%)(0.73%)

5,787 cases

8,075 cases

9,931 cases

10,682 cases

14,858 cases(0.33%)(0.32%)(0.36%)(0.38%)(0.51%)

31,796 cases

50,748 cases

60,034 cases

66,097 cases

92,653 cases(1.82%)(1.99%)(2.19%)(2.35%)(3.20%)

58,478 cases

94,393 cases

109,766 cases

121,577 cases

133,170 cases(3.35%)(3.70%)(4.00%)(4.31%)(4.61%)

Isolation Rates (%)¶
among Data-submitting Facilities†

Inpatient specimens with MIC Value reported by either the broth microdilution method or Etest arecounted.
*The number of duplicates within 30 days is not recounted for the Patients with Specific AMR Bacteria
and Specimen-submitting Patients (See Appendix).
‡Total Isolation Rate = (Total Number of Patients with Speciﬁc AMR Bacteria for Data-submitting
Facilities) /(Total Number of Specimen-submitting Patients for Data-submitting Facilities) x 100¶Isolation Rate = (Number of Patients with Specific AMR Bacteria for Each Facility) / (Number ofSpecimen-submittingPatients for Each Facility) x 100†Data-submitting Facilities indicate facilities included in Annual Open Report 2018
8

This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division

6．Percentage of Facilities Reporting Speciﬁc AMR Bacteria
Percentage of Facilities Reporting Specific AMR Bacteria in 2018 (N=1,947)
Facilities reporting at least one corresponding Specific AMR Bacteria
Facilities reporting no corresponding Specific AMR Bacteria
Methicillin-resistant Staphylococcus aureus(MRSA)

1,943 (99.8%)

Vancomycin-resistant Staphylococcus aureus(VRSA)

1,947 (100.0%)
146 (7.5%)

Vancomycin-resistant Enterococci(VRE)

4 (0.2%)

1,801 (92.5%)
1,321 (67.8%)

Penicillin-resistant Streptococcus pneumoniae(PRSP)

432 (22.2%)

Multidrug-resistant Pseudomonas aeruginosa(MDRP)

1,515 (77.8%)

33 (1.7%)

Multidrug-resistant Acinetobacter spp.(MDRA)

626 (32.2%)

1,914 (98.3%)
1,074 (55.2%)

Carbapenem-resistant Enterobacteriaceae(CRE)

873 (44.8%)

1,660 (85.3%)

Carbapenem-resistant Pseudomonas aeruginosa

287 (14.7%)

1,530 (78.6%)

3rd Generation Cephalosporin-resistant Klebsiella pneumoniae

417 (21.4%)

3rd Generation Cephalosporin-resistant Escherichia coli

1,872 (96.1%)

75 (3.9%)

Fluoroquinolone-resistant Escherichia coli

1,886 (96.9%)

61 (3.1%)

0%

20%

40%

60%

80%

100%

Percentage of Facilities Reporting Specific AMR Bacteria for the Past Five Years
2014
Number of facilities included in Annual Open Report

2015

2016

2017

2018

883

1,435

1,653

1,795

1,947

100.0%

100.0%

99.9%

99.9%

99.8%

Vancomycin-resistant Staphylococcus aureus(VRSA)

0.0%

0.0%

0.0%

0.0%

0.0%

Vancomycin-resistant Enterococci(VRE)

8.8%

7.2%

8.1%

8.7%

7.5%

Penicillin-resistant Streptococcus pneumoniae(PRSP)

80.7%

76.6%

73.9%

70.8%

67.8%

Multidrug-resistant Pseudomonas aeruginosa(MDRP)

44.3%

37.7%

30.2%

26.5%

22.2%

Multidrug-resistant Acinetobacter spp.(MDRA)

3.4%

2.6%

2.4%

1.6%

1.7%

Carbapenem-resistant Enterobacteriaceae(CRE)

81.0%

70.5%

63.0%

56.4%

55.2%

Carbapenem-resistant Pseudomonas aeruginosa

92.6%

89.3%

88.4%

86.5%

85.3%

3rd Generation Cephalosporin-resistant Klebsiella pneumoniae

71.7%

71.0%

69.7%

69.1%

78.6%

3rd Generation Cephalosporin-resistant Escherichia coli

92.1%

90.2%

88.9%

89.1%

96.1%

Fluoroquinolone-resistant Escherichia coli

95.4%

95.7%

96.3%

96.8%

96.9%

Methicillin-resistant Staphylococcus aureus(MRSA)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Percentage of Facilities Reporting Specific AMR Bacteria = (Number of Facilities Reporting at Least one
Corresponding Specific AMR Bacteria) / (Number of Data-submitting Facilities)

9This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Staphylococcus aureus (ALL)†S: Susceptible

I or R : Intermediate or Resistant

PCG (N=287,805)

S or I : Susceptible or IntermediateI: Intermediate

R

ND: Not determined: Resistant

ND:2 (0.0%)

70,719 (24.6%)

217,084 (75.4%)

ND:413 (0.2%)

MPIPC (N=266,047)

138,568 (52.1%)

127,066 (47.8%)

CFX (N=57,604)

30,902 (53.6%)

26,544 (46.1%)

ND:158 (0.3%)

CEZ (N=360,772)

I:17,045 (4.7%) IorR:236 (0.1%)
268,623 (74.5%)

GM (N=345,964)

I:7,220 (2.1%) IorR:174 (0.1%) ND:990 (0.3%)
232,481 (67.2%)
105,099 (30.4%)

EM (N=325,918)

ND:56 (0.0%)74,812 (20.7%)

I:12,510 (3.8%) IorR:312 (0.1%) ND:1 (0.0%)
144,701 (44.4%)
168,391 (51.7%)

SorI:3 (0.0%)

CLDM (N=340,953)

I:4,844 (1.4%) IorR:145 (0.0%)
260,819 (76.5%)

ND:55 (0.0%)

MINO (N=377,507)

I:13,406 (3.6%) IorR:52 (0.0%)
318,090 (84.3%)

ND:1 (0.0%)

45,958 (12.2%)

I:55 (0.0%) ND:1 (0.0%)374,902 (100.0%)

SorI:24 (0.0%)

VCM (N=374,982)

I:27 (0.0%) R:10 (0.0%) ND:18 (0.0%)
336,447 (100.0%)

TEIC (N=336,502)
LVFX (N=358,941)

75,090 (22.0%)

I:2,362 (0.7%) IorR:49 (0.0%) ND:1 (0.0%)
175,557 (48.9%)
180,971 (50.4%)

SorI:1 (0.0%)

LZD (N=286,366)

R:90 (0.0%) ND:2 (0.0%)
286,274 (100.0%)

ST (N=280,200)

R:1,257 (0.4%) ND:532 (0.2%)
278,411 (99.4%)

0%

10%

20%
S

30%

: Susceptible

NS

50%

: Non-susceptible

60%
ND

70%

80%

10%

20%

30%

40%

50%

90%

100%

: Not determined

NS:246 (0.3%)

72,155 (99.7%)

DAP (N=72,401)

0%

40%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted. Duplicates based on
the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
†S. aureus corresponds to Isolated Bacterial Codes 1301 and 1303-1306.
Antibiogram is not created if the total number of isolates is less than 30.

10This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Staphylococcus aureus (MSSA)†S: Susceptible

I or R : Intermediate or Resistant

PCG (N=135,360)

S or I : Susceptible or IntermediateI: Intermediate

R

ND: Not determined: Resistant

ND:2 (0.0%)

71,591 (52.9%)

63,767 (47.1%)

CEZ (N=164,909)

164,789 (99.9%)

CVA/AMPC (N=26,376)

26,357 (99.9%)

IPM (N=149,454)

149,376 (99.9%)

I:71 (0.0%) R:49 (0.0%)

R:19 (0.1%)

I:31 (0.0%) R:47 (0.0%)

GM (N=158,875)

I:3,443 (2.2%) IorR:37 (0.0%) ND:440 (0.3%)
122,520 (77.1%)
32,435 (20.4%)

EM (N=150,809)

111,519 (73.9%)

CLDM (N=155,141)

SorI:2 (0.0%) I:4,434 (2.9%) IorR:68 (0.0%)

I:1,315 (0.8%) IorR:6 (0.0%) R:4,229 (2.7%) ND:17 (0.0%)
149,574 (96.4%)
I:590 (0.3%) IorR:2 (0.0%) R:938 (0.6%)
168,423 (99.1%)

MINO (N=169,953)

137,732 (85.2%)

LVFX (N=161,691)

I:1,638 (1.0%) IorR:9 (0.0%)
22,312 (13.8%)

R:384 (0.3%) ND:226 (0.2%)
126,751 (99.5%)

ST (N=127,361)

0%34,786 (23.1%)

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted. Duplicates based on
the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
†S. aureus (MSSA) corresponds to Isolated Bacterial Codes 1304, 1305 and 1306; and also to Isolated Bacterial Code 1301
susceptible to Antimicrobial Code 1208 (Oxacillin) and 1606 (Cefoxitin).
Antibiogram is not created if the total number of isolates is less than 30.

11This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Staphylococcus aureus (MRSA)†S: Susceptible

I or R : Intermediate or ResistantI: Intermediate

R

ND: Not determined: ResistantI:3,345 (2.0%) IorR:128 (0.1%) ND:550 (0.3%)
69,404 (40.7%)
96,914 (56.9%)

GM (N=170,341)

S:21,304 (13.4%) SorI:1 (0.0%)
EM (N=159,215)

I:7,538 (4.7%) IorR:235 (0.1%) ND:1 (0.0%)
130,136 (81.7%)

I:3,380 (2.0%) IorR:134 (0.1%) ND:38 (0.0%)70,506 (41.7%)
94,991 (56.2%)

CLDM (N=169,049)

I:12,768 (6.7%) IorR:49 (0.0%)
132,069 (69.6%)

MINO (N=189,813)

ND:1 (0.0%)

44,926 (23.7%)

I:36 (0.0%) ND:1 (0.0%)
189,793 (100.0%)

SorI:23 (0.0%)

VCM (N=189,853)

I:22 (0.0%) R:6 (0.0%) ND:10 (0.0%)
169,613 (100.0%)

TEIC (N=169,651)

LVFX (N=179,731)

S or I : Susceptible or Intermediate

S:23,185 (12.9%) I:513 (0.3%) IorR:40 (0.0%)
155,992 (86.8%)

ND:1 (0.0%)

ST (N=138,691)

R:842 (0.6%) ND:305 (0.2%)
137,544 (99.2%)

LZD (N=144,332)

R:42 (0.0%) ND:1 (0.0%)
144,289 (100.0%)

0%

10%

20%
S

30%

: Susceptible

NS

50%

: Non-susceptible

60%
ND

70%

80%

10%

20%

30%

40%

50%

90%

100%

: Not determined

NS:181 (0.5%)

35,437 (99.5%)

DAP (N=35,618)

0%

40%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted. Duplicates based on
the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
†S. aureus (MRSA) corresponds to Isolated Bacterial Codes 1303, and also to Isolated Bacterial Code 1301 Resistant to
Antimicrobial Code 1208 (Oxacillin) or 1606 (Cefoxitin).
Antibiogram is not created if the total number of isolates is less than 30.

12This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Staphylococcus epidermidis†
S: Susceptible

I or R : Intermediate or Resistant

S or I : Susceptible or IntermediateI: Intermediate

R

ND: Not determined: Resistant

S:9,294 (12.3%)

ND:2 (0.0%)

66,146 (87.7%)

PCG (N=75,442)

ND:95 (0.1%)
MPIPC (N=71,766)

54,456 (75.9%)

17,215 (24.0%)

I:5 (0.0%) R:4 (0.0%) ND:3 (0.0%)
94,820 (100.0%)

VCM (N=94,832)

SorI:1 (0.0%)

I:3,273 (3.8%) IorR:9 (0.0%) R:277 (0.3%) ND:1 (0.0%)
83,672 (95.9%)

TEIC (N=87,233)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted. Duplicates based on
the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
†S. epidermidis corresponds to Isolated Bacterial Code 1312.
Antibiogram is not created if the total number of isolates is less than 30.

13This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Coagulase-negative staphylococci (CNS)†S: Susceptible

I or R : Intermediate or Resistant

S or I : Susceptible or IntermediateI: Intermediate

R

ND: Not determined: Resistant

ND:1 (0.0%)

49,052 (79.0%)

PCG (N=62,115) 13,062 (21.0%)

ND:59 (0.1%)
MPIPC (N=61,736)

41,892 (67.9%)

19,785 (32.0%)

I:12 (0.0%) R:17 (0.0%) ND:1 (0.0%)
84,960 (100.0%)

VCM (N=84,990)

I:1,268 (1.7%) IorR:3 (0.0%) R:271 (0.4%)
73,529 (97.9%)

TEIC (N=75,071)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted. Duplicates based on
the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† Coagulase-negative staphylococci (CNS) corresponds to Isolated Bacterial Codes 1311 and 1313-1325 (except Code1312,Staphylococcus epidermidis)
Antibiogram is not created if the total number of isolates is less than 30.

14This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*Enterococcus faecalis†
S: Susceptible

I or R : Intermediate or Resistant

S or I : Susceptible or IntermediateI: Intermediate

R

ND: Not determined: Resistant

R:958 (0.9%) ND:583 (0.6%)
102,482 (98.5%)

PCG (N=104,023)

R:266 (0.2%) ND:2 (0.0%)
118,746 (99.8%)

ABPC (N=119,014)

IorR:68 (0.1%)
EM (N=102,496)

16,281 (15.9%) 32,176 (31.4%)

53,971 (52.7%)

IorR:67 (0.1%)
MINO (N=128,160)

40,231 (31.4%)

22,576 (17.6%)

ND:1 (0.0%)

65,285 (50.9%)

I:11 (0.0%) R:6 (0.0%) ND:5 (0.0%)
129,523 (100.0%)

VCM (N=129,545)

I:2 (0.0%) R:20 (0.0%) ND:1 (0.0%)
115,374 (100.0%)

TEIC (N=115,397)

I:1,760 (1.4%) IorR:22 (0.0%)
107,984 (88.1%)

LVFX (N=122,551)

0%

10%

20%

30%

40%

50%

12,785 (10.4%)

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted. Duplicates based on
the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
†E. faecalis corresponds to Isolated Bacterial Codes 1201 and 1202.
Antibiogram is not created if the total number of isolates is less than 30.

15This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*Enterococcus faecium†S: Susceptible

I or R : Intermediate or Resistant

S or I : Susceptible or IntermediateI: Intermediate

R

ND: Not determined: Resistant

S:4,728 (11.2%)

ND:537 (1.3%)

36,913 (87.5%)

PCG (N=42,178)

S:6,045 (12.3%)

ND:66 (0.1%)

43,096 (87.6%)

ABPC (N=49,207)

S:2,983 (6.8%) IorR:43 (0.1%)
36,160 (83.0%)

4,369 (10.0%)

EM (N=43,555)

IorR:34 (0.1%)

20,890 (38.3%)

15,351 (28.1%)

18,263 (33.5%)

MINO (N=54,540)

ND:2 (0.0%)

I:154 (0.3%) IorR:5 (0.0%) R:473 (0.9%) ND:2 (0.0%)
53,645 (98.8%)

VCM (N=54,279)

I:47 (0.1%) IorR:4 (0.0%) R:309 (0.6%)
48,631 (99.3%)

TEIC (N=48,991)

S:5,345 (10.5%) I:1,390 (2.7%) IorR:63 (0.1%)
44,205 (86.7%)

LVFX (N=51,003)

I:417 (1.0%) R:43 (0.1%)
41,136 (98.9%)

LZD (N=41,596)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted. Duplicates based on
the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
†E. faecium corresponds to Isolated Bacterial Codes 1205 and 1206.
Antibiogram is not created if the total number of isolates is less than 30.

16This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Streptococcus pneumoniae(Cerebrospinal Fluid)†S: Susceptible

I or R : Intermediate or Resistant

S or I : Susceptible or IntermediateI: Intermediate

R

ND: Not determined: Resistant

58 (61.7%)

PCG (N=94)

36 (38.3%)

I:7 (8.0%) R:4 (4.5%)
77 (87.5%)

CTX (N=88)

I:5 (5.3%) R:2 (2.1%)
88 (92.6%)

MEPM (N=95)

I:4 (5.3%)
EM (N=76)

57 (75.0%)

15 (19.7%)

I:4 (5.6%)
36 (50.7%)

CLDM (N=71)

31 (43.7%)

R:2 (2.3%)
86 (97.7%)

LVFX (N=88)

0%

10%

20%
S

30%
: Susceptible

40%
NS

50%

: Non-susceptible

60%
ND

70%

80%

90%

100%

80%

90%

100%

: Not determined

98 (100.0%)

VCM (N=98)

0%

10%

20%

30%

40%

50%

60%

70%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted. Duplicates based on
the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
†S. pneumoniae corresponds to Isolated Bacterial Code 1131.
Antibiogram is not created if the total number of isolates is less than 30.

17This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Streptococcus pneumoniae(Other than Cerebrospinal Fluid)†S: Susceptible

I or R : Intermediate or Resistant

S or I : Susceptible or IntermediateI: Intermediate

R

ND: Not determined: Resistant

I:580 (1.7%) IorR:4 (0.0%)

R:161 (0.5%) ND:5 (0.0%)

32,733 (97.8%)

PCG (N=33,483)

I:375 (1.4%) R:378 (1.4%)
26,251 (97.2%)

CTX (N=27,004)

R:2,096 (6.3%) ND:1 (0.0%)

SorI:5 (0.0%)

27,025 (81.6%)

MEPM (N=33,115)

3,988 (12.0%)

I:774 (2.9%) IorR:15 (0.1%)
EM (N=27,154)

22,075 (81.3%)

4,290 (15.8%)

SorI:2 (0.0%)

I:541 (2.0%) IorR:12 (0.0%)

12,702 (48.0%)

CLDM (N=26,459)

ND:5 (0.0%)

13,197 (49.9%)

I:186 (0.6%) IorR:2 (0.0%)

R:1,462 (4.4%)

31,901 (95.1%)

LVFX (N=33,551)

0%

10%

20%
S

30%

: Susceptible

NS

50%

: Non-susceptible

60%
ND

70%

80%

10%

20%

30%

40%

50%

90%

100%

: Not determined

ND:3 (0.0%)

31,738 (100.0%)

VCM (N=31,741)

0%

40%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted. Duplicates based on
the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
†S. pneumoniae corresponds to Isolated Bacterial Code 1131.
Antibiogram is not created if the total number of isolates is less than 30.

18This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Streptococcus pyogenes†
S: Susceptible

I or R : Intermediate or Resistant

S or I : Susceptible or IntermediateI: Intermediate

R

ND: Not determined: Resistant

SorI:3 (0.1%)

I:27 (0.7%) ND:1 (0.0%)

2,494 (65.4%)

EM (N=3,816)

1,291 (33.8%)

I:22 (0.5%)

SorI:12 (0.3%)

3,900 (87.9%)

CLDM (N=4,435)

0%

10%

20%

S

30%

: Susceptible

40%

NS

50%

: Non-susceptible

501 (11.3%)

60%

ND

70%

80%

90%

100%

: Not determined

4,752 (100.0%)

PCG (N=4,752)

ND:22 (0.5%)
ABPC (N=4,727)

4,705 (99.5%)

CTX (N=3,657)

3,657 (100.0%)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted. Duplicates based on
the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
†S. pyogenes corresponds to Isolated Bacterial Code 1111.
Antibiogram is not created if the total number of isolates is less than 30.

19This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Streptococcus agalactiae†S: Susceptible

I or R : Intermediate or Resistant

S or I : Susceptible or IntermediateI: Intermediate

R

ND: Not determined: Resistant

I:905 (2.7%) IorR:2 (0.0%)

SorI:238 (0.7%)

21,627 (63.9%)

EM (N=33,836)

11,064 (32.7%)

I:773 (1.9%)

SorI:846 (2.1%)

29,727 (74.5%)

CLDM (N=39,906)

0%

10%

20%

S

30%

: Susceptible

40%

NS

8,560 (21.5%)50%: Non-susceptible

60%

ND

70%

80%

100%

: Not determined

NS:2,332 (6.0%)

ND:7 (0.0%)

36,787 (94.0%)

PCG (N=39,126)

NS:438 (1.1%)

ND:323 (0.8%)

38,208 (98.0%)

ABPC (N=38,969)

NS:490 (2.0%)

ND:3 (0.0%)

24,377 (98.0%)

CTX (N=24,870)

0%

90%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted. Duplicates based on
the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
†S. agalactiae corresponds to Isolated Bacterial Code 1114.
Antibiogram is not created if the total number of isolates is less than 30.

20This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Escherichia coli†S: Susceptible

I or R : Intermediate or Resistant

S or I : Susceptible or IntermediateI: Intermediate

R

ND: Not determined: Resistant

SorI:1 (0.0%) I:3,026 (0.9%) IorR:414 (0.1%)ND:132 (0.0%)

169,967 (52.2%)

152,013 (46.7%)

ABPC (N=325,553)

I:11,834 (3.5%) IorR:504 (0.1%)ND:1 (0.0%)
157,345 (46.0%)
172,382 (50.4%)

PIPC (N=342,066)

SorI:86 (0.0%) I:4,036 (1.5%) IorR:11 (0.0%) R:4,555 (1.7%) ND:5 (0.0%)
254,438 (96.7%)
TAZ/PIPC (N=263,131)
CEZ (N=347,491)

I:10,308 (3.0%) IorR:87 (0.0%)
134,360 (38.7%)
133,066 (38.3%)
7,966 (2.3%)

61,704 (17.8%)

CMZ (N=348,832)
CTX (N=251,068)
CAZ (N=352,819)

SorI:949 (0.3%) I:3,243 (0.9%) IorR:86 (0.0%) R:3,026 (0.9%)

341,528 (97.9%)

SorI:215 (0.1%) I:1,407 (0.6%) IorR:392 (0.2%)ND:1,213 (0.5%)
SorI:1,316 (0.4%)

IPM (N=321,043)
MEPM (N=365,600)

I:16,988 (4.8%) IorR:28 (0.0%) ND:170 (0.0%)
43,848 (12.4%)
290,469 (82.3%)
I:6,136 (1.9%) IorR:262 (0.1%)ND:124 (0.0%)
53,822 (16.7%)
261,401 (81.2%)

CFPM (N=321,745)
AZT (N=273,064)

69,019 (27.5%)

178,822 (71.2%)

SorI:830 (0.3%) I:10,953 (4.0%) IorR:49 (0.0%) ND:26 (0.0%)

52,692 (19.3%)

208,514 (76.4%)

SorI:6 (0.0%)

I:296 (0.1%) R:186 (0.1%) ND:1,079 (0.3%)
319,476 (99.5%)

SorI:5 (0.0%)

I:112 (0.0%) R:503 (0.1%) ND:1,086 (0.3%)
363,894 (99.5%)

AMK (N=362,591)

I:804 (0.2%) IorR:1 (0.0%) R:482 (0.1%) ND:25 (0.0%)361,279 (99.6%)

LVFX (N=360,329)

205,787 (57.1%)

0%

SorI:1 (0.0%) I:6,941 (1.9%) IorR:341 (0.1%)

10%

20%

30%

40%

147,259 (40.9%)

50%

60%

70%

80%

90% 100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted. Duplicates based on
the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
†E. coli corresponds to Isolated Bacterial Codes 2001-2007.
Antibiogram is not created if the total number of isolates is less than 30.

21This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Klebsiella pneumoniae†S: Susceptible

I or R : Intermediate or Resistant

ABPC (N=158,654)

S or I : Susceptible or IntermediateI: Intermediate

R

ND: Not determined: Resistant

S:6,015 (3.8%) SorI:1 (0.0%) IorR:261 (0.2%)
125,977 (79.4%)
26,366 (16.6%)

ND:34 (0.0%)

SorI:1 (0.0%) IorR:69 (0.0%) ND:2 (0.0%)

37,856 (22.9%)
23,640 (14.3%)

103,862 (62.8%)

PIPC (N=165,430)

SorI:38 (0.0%) I:2,163 (1.7%) IorR:4 (0.0%) R:3,367 (2.6%) ND:7 (0.0%)
122,199 (95.6%)
TAZ/PIPC (N=127,778)
CEZ (N=166,906)

I:3,393 (2.0%) IorR:19 (0.0%)
23,844 (14.3%)
91,550 (54.9%)
5,187 (3.1%)

42,913 (25.7%)

SorI:436 (0.3%) I:969 (0.6%) IorR:53 (0.0%) R:2,736 (1.6%)

164,593 (97.5%)

CMZ (N=168,787)
CTX (N=122,459)

SorI:63 (0.1%) I:453 (0.4%) IorR:71 (0.1%) ND:686 (0.6%)

11,477 (9.4%)

109,709 (89.6%)

SorI:705 (0.4%) I:1,815 (1.1%) IorR:2 (0.0%) R:9,604 (5.7%) ND:34 (0.0%)
156,937 (92.8%)
CAZ (N=169,097)
CFPM (N=156,485)

I:1,206 (0.8%) IorR:28 (0.0%) R:9,087 (5.8%) ND:27 (0.0%)
146,137 (93.4%)

SorI:452 (0.3%) I:1,040 (0.8%) IorR:1 (0.0%) R:8,909 (6.7%) ND:2 (0.0%)
122,605 (92.2%)
AZT (N=133,009)
SorI:3 (0.0%) I:547 (0.4%) R:484 (0.3%) ND:522 (0.3%)

153,323 (99.0%)

IPM (N=154,879)

SorI:4 (0.0%) I:157 (0.1%) R:866 (0.5%) ND:527 (0.3%)

173,854 (99.1%)

MEPM (N=175,408)
AMK (N=174,259)

I:192 (0.1%) R:176 (0.1%) ND:3 (0.0%)
173,888 (99.8%)

LVFX (N=172,010)

I:2,238 (1.3%) IorR:8 (0.0%) R:5,337 (3.1%) ND:1 (0.0%)
164,426 (95.6%)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90% 100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted. Duplicates based on
the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
†K. pneumoniae corresponds to Isolated Bacterial Code 2351.
Antibiogram is not created if the total number of isolates is less than 30.

22This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*Enterobacter cloacae†
S: Susceptible

I or R : Intermediate or Resistant

S or I : Susceptible or IntermediateI: Intermediate

R

ND: Not determined: Resistant

ABPC (N=64,820)

S:5,117 (7.9%) SorI:2 (0.0%) IorR:70 (0.1%)
52,606 (81.2%)
7,017 (10.8%)

PIPC (N=66,020)

47,237 (71.5%)

ND:8 (0.0%)

I:4,741 (7.2%) IorR:22 (0.0%)
14,020 (21.2%)

SorI:2 (0.0%) IorR:16 (0.0%) ND:3 (0.0%)

5,100 (9.8%)
5,043 (9.7%)

42,022 (80.5%)

TAZ/PIPC (N=52,186)

S:332 (0.5%) SorI:541 (0.8%) I:235 (0.3%) IorR:32 (0.0%) ND:43 (0.1%)
66,834 (98.3%)

CEZ (N=68,017)

CMZ (N=68,013)

S:3,593 (5.3%) SorI:21 (0.0%) I:3,563 (5.2%) IorR:1,005 (1.5%)
59,831 (88.0%)

CTX (N=51,470)
CAZ (N=68,737)
CFPM (N=64,337)

SorI:11 (0.0%) I:1,595 (3.1%) IorR:53 (0.1%) ND:231 (0.4%)

SorI:159 (0.2%) I:2,004 (2.9%) IorR:1 (0.0%) ND:27 (0.0%)

18,060 (26.3%)

48,486 (70.5%)

I:1,010 (1.6%) IorR:11 (0.0%) R:2,515 (3.9%) ND:39 (0.1%)
60,762 (94.4%)
SorI:152 (0.3%) I:2,209 (3.9%) IorR:1 (0.0%) ND:6 (0.0%)

13,952 (24.9%)

39,668 (70.9%)

AZT (N=55,988)

SorI:6 (0.0%)

IPM (N=63,611)

I:2,642 (4.2%) R:712 (1.1%) ND:233 (0.4%)
60,018 (94.4%)

SorI:1 (0.0%) I:185 (0.3%) R:751 (1.1%) ND:237 (0.3%)

69,945 (98.3%)

MEPM (N=71,119)

70,509 (99.8%)

AMK (N=70,659)

I:65 (0.1%) R:85 (0.1%)

SorI:1 (0.0%) I:1,551 (2.2%) IorR:8 (0.0%) R:2,212 (3.2%)

65,620 (94.6%)

LVFX (N=69,392)

0%

16,910 (32.9%)

32,670 (63.5%)

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted. Duplicates based on
the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
†E. cloacae corresponds to Isolated Bacterial Code 2151.
Antibiogram is not created if the total number of isolates is less than 30.

23This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Klebsiella aerogenes（Enterobacter aerogenes）†
S: Susceptible

I or R : Intermediate or Resistant

S or I : Susceptible or IntermediateI: Intermediate

R

ND: Not determined: Resistant

ABPC (N=32,746)

S:2,687 (8.2%) IorR:53 (0.2%)
3,691 (11.3%)

PIPC (N=33,048)

22,406 (67.8%)

ND:6 (0.0%)

26,309 (80.3%)

IorR:12 (0.0%)
5,764 (17.4%)
4,866 (14.7%)

SorI:1 (0.0%) IorR:9 (0.0%) R:1,805 (6.9%) ND:1 (0.0%)

3,863 (14.7%)

20,593 (78.4%)

TAZ/PIPC (N=26,272)

S:270 (0.8%) SorI:1,146 (3.4%) I:226 (0.7%) IorR:22 (0.1%) ND:52 (0.2%)
32,280 (95.0%)

CEZ (N=33,996)

CMZ (N=34,051)

S:1,707 (5.0%) SorI:10 (0.0%) I:1,404 (4.1%) IorR:577 (1.7%)
30,353 (89.1%)
SorI:15 (0.1%) I:567 (2.2%) IorR:32 (0.1%) ND:94 (0.4%)

8,520 (33.4%)

16,265 (63.8%)

CTX (N=25,493)

SorI:79 (0.2%) I:1,142 (3.3%) IorR:6 (0.0%) ND:18 (0.1%)

9,503 (27.8%)

23,394 (68.5%)

CAZ (N=34,142)

I:167 (0.5%) IorR:7 (0.0%) R:442 (1.4%) ND:23 (0.1%)
31,577 (98.0%)

CFPM (N=32,216)

SorI:43 (0.2%) I:2,110 (7.5%) IorR:4 (0.0%) ND:8 (0.0%)

5,421 (19.2%)

20,695 (73.2%)

AZT (N=28,281)

SorI:3 (0.0%) R:808 (2.6%) ND:54 (0.2%)

26,639 (85.1%)

IPM (N=31,288)

3,784 (12.1%)

MEPM (N=35,448)

I:96 (0.3%) R:289 (0.8%) ND:54 (0.2%)
35,009 (98.8%)

AMK (N=35,214)

35,171 (99.9%)

LVFX (N=34,383)

I:220 (0.6%) IorR:1 (0.0%) R:306 (0.9%)
33,856 (98.5%)

0%

10%

20%

30%

40%

50%

60%

I:25 (0.1%) R:18 (0.1%)

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted. Duplicates based on
the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
†K. aerogenes corresponds to Isolated Bacterial Code 2152.
Antibiogram is not created if the total number of isolates is less than 30.

24This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Citrobacter freundii†
S: Susceptible

I or R : Intermediate or Resistant

ABPC (N=18,678)

S or I : Susceptible or IntermediateI: Intermediate

R

ND: Not determined: ResistantIorR:41 (0.2%)
4,973 (26.6%) 2,784 (14.9%)

I:1,525 (8.1%) IorR:14 (0.1%)
4,189 (22.2%)

13,133 (69.6%)

PIPC (N=18,861)

ND:1 (0.0%)

10,879 (58.2%)

I:1,198 (7.9%) IorR:2 (0.0%) R:604 (4.0%)
13,383 (88.1%)

TAZ/PIPC (N=15,187)

S:170 (0.9%) SorI:388 (2.0%) I:149 (0.8%) IorR:4 (0.0%) ND:24 (0.1%)
18,829 (96.2%)

CEZ (N=19,564)

CMZ (N=19,497)

7,687 (39.4%)

SorI:46 (0.2%) IorR:196 (1.0%)

6,192 (31.8%)

5,376 (27.6%)

SorI:6 (0.0%) I:244 (1.7%) IorR:25 (0.2%) ND:70 (0.5%)

4,120 (28.7%)

9,914 (68.9%)

CTX (N=14,379)

SorI:62 (0.3%) I:365 (1.8%) IorR:18 (0.1%) ND:5 (0.0%)

5,000 (25.2%)

14,377 (72.5%)

CAZ (N=19,827)

I:115 (0.6%) IorR:4 (0.0%) R:334 (1.8%) ND:10 (0.1%)
18,025 (97.5%)

CFPM (N=18,488)

SorI:39 (0.2%) I:556 (3.5%) IorR:15 (0.1%) ND:6 (0.0%)

3,678 (22.9%)

11,746 (73.2%)

AZT (N=16,040)
IPM (N=18,150)

I:564 (3.1%) R:89 (0.5%) ND:52 (0.3%)
17,445 (96.1%)

MEPM (N=20,604)

I:11 (0.1%) R:109 (0.5%) ND:52 (0.3%)
20,432 (99.2%)

AMK (N=20,227)

20,180 (99.8%)

I:433 (2.2%) IorR:2 (0.0%) R:736 (3.7%)
18,866 (94.2%)

LVFX (N=20,037)

0%

I:25 (0.1%) R:22 (0.1%)

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted. Duplicates based on
the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
†C. freundii corresponds to Isolated Bacterial Code 2051.
Antibiogram is not created if the total number of isolates is less than 30.

25

This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Citrobacter koseri†
S: Susceptible

I or R : Intermediate or Resistant

ABPC (N=12,784)

S or I : Susceptible or IntermediateI: Intermediate

R

ND: Not determined: Resistant

S:96 (0.8%) I:516 (4.0%) IorR:25 (0.2%)
12,135 (94.9%)

PIPC (N=13,797)

IorR:12 (0.1%)
4,264 (30.9%)
4,842 (35.1%)

4,679 (33.9%)

SorI:2 (0.0%) I:175 (1.7%) R:282 (2.7%) ND:2 (0.0%)

9,960 (95.6%)

TAZ/PIPC (N=10,421)
CEZ (N=13,663)

ND:12 (0.1%)

I:321 (2.3%)
7,373 (54.0%) 2,054 (15.0%)
408 (3.0%)

3,507 (25.7%)

SorI:23 (0.2%) I:377 (2.7%) IorR:9 (0.1%) R:490 (3.5%)

13,090 (93.6%)

CMZ (N=13,989)

SorI:1 (0.0%) I:73 (0.8%) IorR:3 (0.0%) ND:28 (0.3%)

1,079 (11.5%)

8,196 (87.4%)

CTX (N=9,380)

SorI:42 (0.3%) I:135 (1.0%) IorR:2 (0.0%) R:1,165 (8.4%) ND:15 (0.1%)
12,452 (90.2%)
CAZ (N=13,811)
CFPM (N=12,954)

I:70 (0.5%) IorR:16 (0.1%) R:759 (5.9%)
12,109 (93.5%)

AZT (N=10,464)

9,306 (88.9%)

SorI:16 (0.2%) I:69 (0.7%) IorR:2 (0.0%)

SorI:1 (0.0%) I:49 (0.4%) R:16 (0.1%) ND:20 (0.2%)

12,501 (99.3%)

IPM (N=12,587)

I:4 (0.0%) R:23 (0.2%) ND:20 (0.1%)
14,489 (99.7%)

SorI:1 (0.0%)

MEPM (N=14,537)

14,371 (99.7%)

AMK (N=14,418)

I:30 (0.2%) R:17 (0.1%)

I:229 (1.6%) IorR:5 (0.0%) R:969 (6.8%)
13,063 (91.6%)

LVFX (N=14,266)

0%

1,071 (10.2%)

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted. Duplicates based on
the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
†C. koseri corresponds to Isolated Bacterial Code 2052.
Antibiogram is not created if the total number of isolates is less than 30.

26This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Proteus mirabilis†
S: Susceptible

I or R : Intermediate or Resistant

S or I : Susceptible or IntermediateI: Intermediate

R

ND: Not determined: Resistant

ABPC (N=29,797)

I:262 (0.9%) IorR:19 (0.1%) ND:48 (0.2%)
10,220 (34.3%)
19,248 (64.6%)

PIPC (N=33,613)

22,211 (66.1%)

SorI:9 (0.0%) I:73 (0.3%) R:37 (0.1%)

25,044 (99.5%)

TAZ/PIPC (N=25,163)
CEZ (N=33,709)

I:1,688 (5.0%) IorR:62 (0.2%)
9,652 (28.7%)

S:3,666 (10.9%) IorR:3 (0.0%)
12,522 (37.1%)
13,291 (39.4%) 3,199 (9.5%)
1,028 (3.0%)
SorI:55 (0.2%) I:146 (0.4%) IorR:7 (0.0%) R:199 (0.6%)

32,870 (98.8%)

CMZ (N=33,277)

SorI:8 (0.0%) I:148 (0.7%) IorR:17 (0.1%) ND:104 (0.5%)

4,552 (21.0%)

16,844 (77.7%)

CTX (N=21,673)

SorI:118 (0.4%) I:247 (0.8%) IorR:1 (0.0%) R:395 (1.2%) ND:1 (0.0%)
32,094 (97.7%)
CAZ (N=32,856)

25,768 (84.4%)

CFPM (N=30,543)

SorI:81 (0.3%) I:244 (1.0%) IorR:5 (0.0%) R:1,979 (8.1%)

22,103 (90.5%)

AZT (N=24,412)

SorI:483 (2.9%)

ND:84 (0.5%)

3,587 (21.8%) 3,394 (20.6%)

8,889 (54.1%)

IPM (N=16,437)

SorI:1 (0.0%) I:17 (0.0%) R:19 (0.1%) ND:85 (0.2%)

34,797 (99.7%)

MEPM (N=34,919)

I:73 (0.2%) R:70 (0.2%) ND:2 (0.0%)
34,504 (99.6%)

AMK (N=34,649)
LVFX (N=34,820)

0%

I:472 (1.5%) IorR:56 (0.2%)
4,247 (13.9%)

10%

20%

26,436 (75.9%)

I:3,017 (8.7%) IorR:17 (0.0%)
5,350 (15.4%)

30%

60%

40%

50%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted. Duplicates based on
the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
†P. mirabilis corresponds to Isolated Bacterial Code 2201.
Antibiogram is not created if the total number of isolates is less than 30.

27

This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Proteus vulgaris†
S: Susceptible

I or R : Intermediate or Resistant

ABPC (N=6,899)

S or I : Susceptible or IntermediateI: Intermediate

R

ND: Not determined: Resistant

S:289 (4.2%) I:77 (1.1%) IorR:8 (0.1%)
6,524 (94.6%)

SorI:4 (0.1%) I:16 (0.3%) R:12 (0.2%)

5,731 (99.4%)

TAZ/PIPC (N=5,763)
CEZ (N=7,333)

IorR:2 (0.0%)
1,108 (15.7%)
1,171 (16.5%)

4,798 (67.8%)

PIPC (N=7,079)

ND:1 (0.0%)

S:20 (0.3%) SorI:128 (1.7%) I:30 (0.4%) IorR:2 (0.0%) ND:9 (0.1%)
7,144 (97.4%)
SorI:7 (0.1%) I:22 (0.3%) IorR:1 (0.0%) R:31 (0.4%)

7,164 (99.2%)

CMZ (N=7,225)

I:243 (4.4%) IorR:4 (0.1%) ND:19 (0.3%)
1,141 (20.9%)
4,062 (74.2%)

SorI:3 (0.1%)

CTX (N=5,472)

SorI:36 (0.5%) I:55 (0.8%) R:88 (1.2%)

7,126 (97.5%)

CAZ (N=7,305)

I:38 (0.6%) IorR:1 (0.0%) R:87 (1.3%) ND:4 (0.1%)
6,631 (98.1%)

CFPM (N=6,761)

SorI:18 (0.3%) I:123 (2.1%)

598 (10.0%)

5,229 (87.6%)

AZT (N=5,968)

SorI:4 (0.1%) IorR:2 (0.0%) ND:23 (0.6%)985 (23.6%)

2,316 (55.4%)

IPM (N=4,177)

847 (20.3%)

SorI:1 (0.0%) I:3 (0.0%) R:6 (0.1%) ND:23 (0.3%)

7,561 (99.6%)

MEPM (N=7,594)
AMK (N=7,539)

I:6 (0.1%) R:13 (0.2%) ND:1 (0.0%)
7,519 (99.7%)

LVFX (N=7,454)

7,335 (98.4%)
0%

10%

20%

30%

40%

50%

60%

I:35 (0.5%) R:84 (1.1%)

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted. Duplicates based on
the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
†P. vulgaris corresponds to Isolated Bacterial Code 2202.
Antibiogram is not created if the total number of isolates is less than 30.

28This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Serratia marcescens†S: Susceptible

I or R : Intermediate or Resistant

S or I : Susceptible or IntermediateI: Intermediate

R

ND: Not determined: Resistant

S:1,528 (4.7%) IorR:61 (0.2%)

ABPC (N=32,526) 3,344 (10.3%)

26,591 (76.4%)

PIPC (N=34,808)

IorR:35 (0.1%) R:2,818 (8.1%)
5,364 (15.4%)

SorI:5 (0.0%) IorR:6 (0.0%) R:1,139 (4.2%) ND:1 (0.0%)

2,696 (9.9%)

23,271 (85.8%)

TAZ/PIPC (N=27,118)
CEZ (N=35,508)

ND:58 (0.2%)

27,535 (84.7%)

S:12 (0.0%) SorI:20 (0.1%) I:4 (0.0%) IorR:21 (0.1%)
35,451 (99.8%)

CMZ (N=35,126)

SorI:72 (0.2%) IorR:91 (0.3%) R:3,145 (9.0%) ND:1 (0.0%)

3,595 (10.2%)

28,222 (80.3%)

SorI:11 (0.1%) I:657 (6.2%) IorR:28 (0.3%) ND:99 (0.9%)

2,129 (20.2%)

7,622 (72.3%)

CTX (N=10,546)

SorI:103 (0.3%) I:585 (1.7%) R:3,033 (8.6%) ND:1 (0.0%)

31,600 (89.5%)

CAZ (N=35,322)

I:163 (0.5%) IorR:1 (0.0%) R:305 (0.9%) ND:46 (0.1%)
32,692 (98.4%)

CFPM (N=33,207)

SorI:79 (0.3%) I:888 (3.2%) IorR:1 (0.0%) R:2,289 (8.2%)

24,511 (88.3%)

AZT (N=27,768)

I:1,280 (4.4%) IorR:1 (0.0%) R:455 (1.6%) ND:99 (0.3%)
27,365 (93.7%)

IPM (N=29,200)

SorI:4 (0.0%) I:40 (0.1%) R:90 (0.2%) ND:99 (0.3%)

36,763 (99.4%)

MEPM (N=36,996)
AMK (N=36,642)

I:241 (0.7%) R:96 (0.3%) ND:2 (0.0%)
36,303 (99.1%)

LVFX (N=36,548)

I:1,466 (4.0%) IorR:5 (0.0%) R:1,497 (4.1%)
33,580 (91.9%)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted. Duplicates based on
the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
†S. marcescens corresponds to Isolated Bacterial Code 2101.
Antibiogram is not created if the total number of isolates is less than 30.

29This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Pseudomonas aeruginosa†
S: Susceptible

I or R : Intermediate or Resistant

SorI:1 (0.0%)
CAZ (N=203,554)

IPM (N=188,778): Intermediate

ND: Not determined: ResistantIorR:50 (0.0%)
20,600 (10.0%)
20,585 (10.0%)

SorI:23 (0.0%) I:14,740 (8.5%) IorR:39 (0.0%) R:14,019 (8.1%)

143,927 (83.3%)

I:10,446 (5.1%) IorR:308 (0.2%)R:17,098 (8.4%) ND:1 (0.0%)
175,700 (86.3%)

116,783 (71.9%)

AZT (N=162,365)

CFPM (N=194,385)

IR

165,623 (80.1%)

PIPC (N=206,858)

TAZ/PIPC (N=172,748)

S or I : Susceptible or Intermediate

IorR:540 (0.3%)ND:159 (0.1%)
21,311 (13.1%)
23,572 (14.5%)

I:15,111 (7.8%) IorR:23 (0.0%) R:11,631 (6.0%) ND:3 (0.0%)
167,617 (86.2%)
SorI:380 (0.2%) I:6,558 (3.5%) IorR:263 (0.1%)ND:1 (0.0%)30,619 (16.2%)

150,957 (80.0%)

SorI:406 (0.2%) I:10,201 (4.9%) IorR:136 (0.1%)
22,708 (10.9%)
175,698 (84.0%)

MEPM (N=209,149)

SorI:5 (0.0%) I:16,181 (8.8%) IorR:17 (0.0%) R:5,267 (2.9%) ND:1 (0.0%)

162,664 (88.3%)

GM (N=184,135)

AMK (N=209,413)

I:2,900 (1.4%) IorR:8 (0.0%) R:1,961 (0.9%) ND:1 (0.0%)
204,543 (97.7%)

167,451 (83.8%)

LVFX (N=199,760)

0%

10%

20%

30%

40%

50%

I:11,961 (6.0%) IorR:52 (0.0%)
20,296 (10.2%)

60%

70%

80%

90% 100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted. Duplicates based on
the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
†P. aeruginosa corresponds to Isolated Bacterial Code 4001.
Antibiogram is not created if the total number of isolates is less than 30.

30This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Acinetobacter spp.†
S: Susceptible

I or R : Intermediate or Resistant

S or I : Susceptible or IntermediateI: Intermediate

R

ND: Not determined: ResistantIorR:8 (0.0%)
3,468 (12.4%)
2,886 (10.3%)

21,543 (77.2%)

PIPC (N=27,905)

I:548 (4.5%) IorR:33 (0.3%) ND:1 (0.0%)
10,439 (85.8%)
1,150 (9.4%)

TAZ/PIPC (N=12,171)

SorI:3 (0.0%) I:227 (1.7%) IorR:3 (0.0%) R:576 (4.4%) ND:2 (0.0%)

12,300 (93.8%)

SBT/ABPC (N=13,111)

I:1,404 (5.0%) IorR:382 (1.4%)R:2,124 (7.6%)
24,167 (86.1%)

CAZ (N=28,077)

CFPM (N=26,616)

I:1,285 (4.8%) IorR:3 (0.0%) R:1,804 (6.8%) ND:7 (0.0%)
23,517 (88.4%)

IPM (N=16,995)

I:82 (0.5%) IorR:13 (0.1%) R:336 (2.0%) ND:12 (0.1%)
16,552 (97.4%)

MEPM (N=29,024)

I:139 (0.5%) IorR:26 (0.1%) R:430 (1.5%) ND:70 (0.2%)
28,359 (97.7%)

GM (N=25,465)

I:922 (3.6%) IorR:1 (0.0%) R:1,980 (7.8%)
22,562 (88.6%)

AMK (N=28,437)

I:149 (0.5%) IorR:2 (0.0%) R:575 (2.0%)
27,711 (97.4%)

LVFX (N=28,209)

I:1,438 (5.1%) IorR:4 (0.0%) R:1,987 (7.0%)
24,780 (87.8%)0%

ND:12 (0.1%)

19,901 (89.9%)

ST (N=22,143)

10%

20%

30%

40%

50%

2,230 (10.1%)

60%

70%

80%

90%

100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted. Duplicates based on
the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
†Acinetobacter spp. correspond to Isolated Bacterial Codes 4400-4403.
Antibiogram is not created if the total number of isolates is less than 30.

31This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

Annual Open Report 2018 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【CLSI2012 Version】
Clinical Laboratory Division
7．Antimicrobial Susceptibility of Major Bacteria*
Haemophilus influenzae†S: Susceptible

I or R : Intermediate or Resistant

S or I : Susceptible or IntermediateI: Intermediate

R

ND: Not determined

IorR:1 (0.0%) ND:1 (0.0%)
18,864 (43.8%)
8,402 (19.5%)

15,756 (36.6%)

ABPC (N=43,024): Resistant

ND:2 (0.0%)

13,821 (35.7%)

24,934 (64.3%)

SBT/ABPC (N=38,757)

ND:1 (0.0%)

5,149 (20.0%)

20,590 (80.0%)

CVA/AMPC (N=25,740)
CAM (N=40,644)

IorR:152 (0.4%) R:1,629 (4.0%) ND:113 (0.3%)
6,769 (16.7%)
31,981 (78.7%)

TC (N=16,131)

I:38 (0.2%) IorR:3 (0.0%)
15,960 (98.9%)

0%

10%

S

20%

30%

: Susceptible

NS

40%

50%

: Non-susceptible

60%

ND

70%

R:130 (0.8%)

80%

90% 100%: Not determined

NS:545 (1.8%)
29,929 (98.2%)

CTX (N=30,474)

NS:1,644 (3.7%)
42,931 (96.3%)

MEPM (N=44,577)

NS:1,462 (3.3%)

ND:3 (0.0%)42,897 (96.7%)

LVFX (N=44,362)

0%

ND:2 (0.0%)

10%

20%

30%

40%

50%

60%

70%

80%

90% 100%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted. Duplicates based on
the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
†H. influenzae corresponds to Isolated Bacterial Codes 3201, 3202, 3203, 3205, 3208, 3211, 3214, 3217, 3220 and 3223.
Antibiogram is not created if the total number of isolates is less than 30.

32This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 16, 2019

Date of Publication (English Version) :July 30, 2019

【Appendix 1
Isolated
Bacterium
Methicillin-Resistant
Staphylococcus aureus(MRSA)
VancomycinResistant
Staphylococcus aureus(VRSA)
VancomycinResistant Enterococci(VRE)

Penicillin-Resistant
Streptococcus
pneumoniae(PRSP)
Multidrug-ResistantPseudomonas
aeruginosa(MDRP)

Multidrug-ResistantAcinetobacter spp.
(MDRA)

CarbapenemResistantEnterobacteriaceae(CRE)

Interpretive Criteria for Specific AMR Bacteria based on the Broth Microdilution Method】
Comments*
S. aureus resistant to oxacillin and/or
cefoxitin by the broth microdilution
method or methicillin-resistant S. aureus
detected on selective media
S. aureus resistant to vancomycin

Enterococcus spp. resistant† tovancomycin by the broth microdilution
method or vancomycin-resistantenterococci detected on selective media
Note: Excluding species that were not
identified within Enterococcus sp.
S. pneumoniae resistant† topenicillin G

MIC Values by BrothMicrodilution Method
oxacillin ≥ 4 μg/mL
cefoxitin ≥ 8 μg/mL

Isolated Bacterial
Code Ver.5.1
1301, 1303

vancomycin ≥ 16 μg/mL

1301,1303–1306

vancomycin ≥ 16 μg/mL†

1201,1202,1205,
1206,1209,1210,
1213–1217

penicillin G ≥ 0.125 μg/mL†

1131

P. aeruginosa satisfying all of thefollowing criteria:
1. Resistant† to carbapenems(imipenem and/or meropenem)
2. Resistant† to aminoglycosides(amikacin)
3. Resistant to fluoroquinolones (any ofnorfloxacin, ofloxacin, levofloxacin,
lomefloxacin, ciprofloxacin).
Acinetobacter spp. satisfying all of thefollowing criteria:
1. Resistant to carbapenems (imipenem
and/or meropenem)
2. Resistant† to aminoglycosides(amikacin)
3. Resistant to fluoroquinolones (any oflevofloxacin, ciprofloxacin)

1. imipenem ≥ 16 μg/mL†,
meropenem ≥ 16 μg/mL†
2. amikacin ≥ 32 μg/mL†
3. norfloxacin ≥ 16 μg/mL,
ofloxacin ≥ 8 μg/mL,
levofloxacin ≥ 8 μg/mL,
lomefloxacin≥ 8 μg/mL,
ciprofloxacin ≥ 4 μg/mL

4001

1. imipenem ≥ 16 μg/mL†,
meropenem ≥ 16 μg/mL†
2. amikacin ≥ 32 μg/mL†
3. levofloxacin ≥ 8 μg/mL,
ciprofloxacin ≥ 4 μg/mL

4400–4403

Enterobacteriaceae satisfying one of thefollowing criteria.
1. Resistant† to meropenem
2. Resistant† to imipenem and also
resistant to cefmetazole

meropenem ≥ 2 μg/mL†,
imipenem ≥ 2 μg/mL†
and also
cefmetazole ≥ 64 μg/mL

2000-2691,
3150-3151

Isolated
Bacterium
CarbapenemResistantPseudomonas
aeruginosa
3rd Generation
CephalosporinResistant Klebsiellapneumoniae
3rd Generation
CephalosporinResistantEscherichia coli
FluoroquinoloneResistantEscherichia coli

Comments*
P. aeruginosa resistant to imipenem
and/or meropenem

MIC Values by BrothMicrodilution Method
imipenem ≥ 16 μg/mL†,
meropenem ≥ 16 μg/mL†

Isolated Bacterial
Code Ver.5.1
4001

K. pneumoniae resistant to cefotaxime
and/or ceftriaxone and/or ceftazidime

cefotaxime ≥ 4 μg/mL,
ceftriaxone ≥ 4 μg/mL,
ceftazidime ≥ 16 μg/mL

2351

E. coli resistant to cefotaxime and/or
ceftriaxone and/or ceftazidime

cefotaxime ≥ 4 μg/mL,
ceftriaxone ≥ 4 μg/mL,
ceftazidime ≥ 16 μg/mL

2001–2007

E. coli resistant to fluoroquinolones (anyof norfloxacin, ofloxacin, levofloxacin,
lomefloxacin, and ciprofloxacin)

norfloxacin ≥ 16 μg/mL,
ofloxacin ≥ 8 μg/mL,
levofloxacin ≥ 8 μg/mL,
lomefloxacin ≥ 8 μg/mL,
ciprofloxacin ≥ 4 μg/mL

2001–2007* In principle, RIS interpretation is based on the CLSI2012 (M100-S22) guidelines† Criteria are based on the Infectious Diseases Control Law

【Appendix 2

Method to Eliminate Duplicates of Annual Report】

1. Rule of Counting Days
“Day 1” is defined as the day after the "Specimen Reception Date". For example, if
a specimen is received on March 1, “Day 1” will be March 2 and “Day 30” will be
March 31.
wi thin 30 days
Example)Ma rchApri lMar 31"Da y 30"

Mar 2
"Da y 1"
Mar 1
"Specimen
Reception Date"

Example28 daysSpecimen
Reception Date

2. Number of "Specimen-submitting Patients"
The number of “Specimen-submitting Patients” is equal to the number of
inpatients whose specimens were submitted, regardless of the specimen sources.
If more than one specimen is submitted by one patient within 30 days, thenumber of “Specimen-submitting Patients” is defined as one. This is how weeliminate duplicates.
Example)Speci men
Receiption Date

3. Number of Patients with Major/Specific AMR Bacteria
The same method used to eliminate duplicate “Specimen-submitting Patients”
records is applied to “Patients with Major/Specific AMR Bacteria”. If more than one
identical bacterium is isolated from the same patient within 30 days, the numberof “Patients with Major/Specific AMR Bacteria” is not recounted.
To obtain the number of “Patients with Specific AMR Bacteria”, first the data
regarding pathogens which meet “Specific AMR Bacteria” criteria are extracted.
Then the method mentioned above is applied to eliminate duplicates.

Ma rchMar 2Apri lMar 30

Apr 10

Ma y
May 15Speci men
Speci mens ubmitting
Pa ti ents

The number of "Specimen-submitting
Pa ti ents" is not recounted i f thes econd specimen is s ubmitted within
30 da ys

The number of "Specimen-submitting
Pa ti ents" is recounted if the second
s pecimen is submitted on after 31
da ys

Ma rchMar 2

35 days

39 days

Apri lMar 30

Apr 10

Ma y
May 15Specimen
Pts with Major/
Specific AMR
bacteria

The number of "Pa tients with
Ma jor/Specific AMR Ba cteria" is notrecounted i f an i solated pathogen is
the s ame species as one identified
wi thin the past 30 da ys

The number of "Pa tiens with
Ma jor/Specific AMR Ba cteria" isrecounted i f the same pathogen i s
i s olated again on or a fter 31 da ys

4. Definition of Isolates Based on the Results of Antimicrobial Susceptibility Testing(AST)
If the AST results differ* between the same bacteria isolated within 30 days, eachof them is counted separately.
*Difference of AST is determined by satisfying any of the following four criteria:① More than four-fold difference in the MIC value; however,
MIC > 2 is equivalent to MIC ≥ 4 and is interpreted as MIC = 4, and
MIC < 16 is equivalent to MIC ≦ 16 and is interpreted as MIC = 16
② Findings of “R and S” on RIS interpretation③ Findings of “- and ++”, “+ and +++”, or “- and +++” on +/- interpretation④ Fewer than five duplicate antimicrobial agents among testings

【Appendix 2

Method to Eliminate Duplicates of Annual Report】

5. Method for Eliminating Duplicates Based on the Results of AST-

The following method will be applied to eliminate duplicates if “Identical Bacteria”
are detected more than once from the same patient within 30 days, according to
the criteria in Section 4.
With regard to the “Specimen Reception Date”, whichever is the earliest will be
adoptedData in which the greatest number of antimicrobial agents tested will be adopted
as the “Results of AST”
Adopted Specimen
Reception Date

Adopted Resultof AST

Example 1

Number of Antimicrobial Agents Tested: SEVEN on March 1 and ONE on March 31

Mar 1Within 30 days

Mar 31

SEVEN

March 1

SEVEN

ONE

Example 2

Number of Antimicrobial Agents Tested: TWO on March 1 and FIVE on March 31

Mar 1


TWO

Within 30 days

Mar 31March 1FIVE
FIVE

【Appendix 3

Box Plot Chart】

1. Box Plot Chart
The chart represents the data distribution of the facilities.

Example※Percentile represents the position of a single data value within a group of
samples in ascending order. For example, if a group contains 100 samples,
then the 10th percentile refers to the position of the 10th smallest value inthe group.
ｎn

2.

Box Plot Chart of Feedback Reports

Example